In this article, we will take a look at 7 Oversold European Stocks to Buy.
European equities fell on March 27 while oil prices remained high, as concerns about the impact of conflict in the Middle East persisted despite US President Donald Trump’s decision to extend the deadline for renewed aerial strikes on Iranian energy facilities until April 6. The Euro Stoxx 50 is down more than 1.3%, and Germany’s DAX is down more than 1.5%.
Against this context, oil prices stayed persistently high at the close of a volatile trading week. The Brent crude futures contract, which expires in May, was recently up 2.6% at $104.53 a barrel, reversing much of the earlier decline and remaining comfortably above pre-war levels.
Expectations have risen that the European Central Bank will be obliged to consider increasing its interest rates in the coming months, a view bolstered by statements from certain ECB governors the previous week.
ECB President Christine Lagarde has suggested that financial markets might be underestimating the scale of the energy crisis, a situation that’s beginning to ripple through the world’s economies. She pointed out that Europe could be particularly vulnerable, given its reliance on energy markets and essential materials like helium, a key component in semiconductor production. Lagarde further indicated that the repercussions could be felt for years, with a slow and steady economic rebound expected.
Our Methodology
For this list, we used stock screeners to identify US-listed European stocks with a Relative Strength Index (RSI) below 30. These stocks are widely held by hedge funds and followed by analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. Qiagen N.V. (NYSE:QGEN)
Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V. (NYSE:QGEN) to Buy from Hold, maintaining a $54 price target on the company’s shares. The firm stated that Qiagen’s stock had declined over 30% since late January’s M&A stories and accompanying downgrade, essentially pricing out any buyout premium.
According to the firm, the company’s 2026 outlook is back-end heavy, which is common among Diagnostics and Life Sciences competitors and is due in part to mechanical impacts reasonably reflected in current consensus estimates.
Qiagen N.V. (NYSE:QGEN) also outlined its strategy at the Barclays 28th Annual Global Healthcare Conference on March 10, emphasizing sustainable development objectives in the midst of a CEO transition.
Despite macroeconomic challenges and the temporary impact of discontinued products such as NeuMoDx, the company reiterated its 5% full-year growth estimate. Growth is likely to improve in the second half, boosted by the introduction of new sample-preparation products that could add up to 200 basis points to results.
Qiagen N.V. (NYSE:QGEN), based in the Netherlands, is a global leader in Sample-to-Insight solutions. The company provides technologies for extracting and analyzing DNA, RNA, and proteins from various samples.
6. Alvotech (NASDAQ:ALVO)
Alvotech (NASDAQ:ALVO) ranks among the oversold European stocks to buy. On March 19, Alvotech (NASDAQ:ALVO) revealed its full-year and Q4 2025 earnings results, delivering revenues of $593 million for the year, representing a 21% year-over-year growth and greatly surpassing analyst projections with Q4 EPS of $0.03 versus a predicted loss of $0.0833.
Alvotech (NASDAQ:ALVO) has revealed 15 distinct programs aimed at key biologics, such as Xolair, Entyvio, Eylea HD, and Keytruda, with over 30 biosimilar candidates in development. For these reported candidates, the total addressable market is more than $185 billion.
Despite barriers to regulation in the US, Alvotech’s on-market products have managed to gain traction in overseas markets. The company’s biosimilar of Humira, AVT02, profited from the originator’s dwindling US market share, which declined from 70% to around 45% by the end of 2025.
On the manufacturing side, Alvotech (NASDAQ:ALVO) is extending its perfusion manufacturing capacity in Reykjavik by adding a third medical component and an additional product production unit.
Alvotech (NASDAQ:ALVO) is a biotechnology company specializing in the development, manufacturing, and commercialization of biosimilar medicines to provide affordable biologic alternatives globally.
While we acknowledge the potential of ALVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALVO and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Oversold European Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
